RAG-17

DB18503InvestigationalGene Therapies

RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase (SOD).

Mechanism: Pharmacologically active on Superoxide dismutase 1 (SOD1)
Curator reviewed
Code names: RAG-17

What you can answer from here — as of October 05, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of RAG-17, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.